Sapacitabine

Summary

Sapacitabine (CHEMBL2105681) is a phase-3 clinical-stage small-molecule antineoplastic agent; indicated across 6 conditions including acute myeloid leukemia and primary cutaneous t-cell non-hodgkin lymphoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 6 conditions
• Clinical trials: 9
• Chemistry: 490.6 Da · C26H42N4O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105681
Name	Sapacitabine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	153970
ChEBI	CHEBI:145429
Molecular formula	C26H42N4O5
Molecular weight	490.6
InChIKey	LBGFKUUHOPIEMA-PEARBKPGSA-N

SMILES: CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)C#N

IUPAC name: N-[1-[(2R,3S,4S,5R)-3-cyano-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]hexadecanamide

ChEBI definition: A nucleoside analogue resulting from the formal condensation of the carboxy group of hexadecanoic acid with the amino group of CNDAC. It is the prodrug of CNDAC and is currently in clinical development for the treatment of acute myeloid leukemia (AML).

Pharmacological roles (ChEBI): antineoplastic agent, prodrug, DNA synthesis inhibitor.

Other ChEBI roles (chemical / environmental): antimetabolite.

Also known as: CS-682, CYC-682, CYC682, Sapacitabina, Sapacitabine, SAPACITABINE

Patent coverage: 775 distinct patent families (2,236 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
primary cutaneous T-cell non-Hodgkin lymphoma	2	MONDO:0000607	EFO:0002913
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
leukemia	2	MONDO:0005059	EFO:0000565
neoplasm	1	MONDO:0005070	EFO:0000616
breast neoplasm	1	MONDO:0021100	MONDO:0007254

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	4
PHASE1	3
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01303796	PHASE3	COMPLETED	A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00476554	PHASE2	TERMINATED	A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
NCT00590187	PHASE2	COMPLETED	Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
NCT00885963	PHASE2	TERMINATED	A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
NCT01211457	PHASE1/PHASE2	UNKNOWN	Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
NCT01253460	PHASE2	TERMINATED	Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
NCT03641755	PHASE1	ACTIVE_NOT_RECRUITING	Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
NCT00380653	PHASE1	COMPLETED	Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
NCT00999401	PHASE1	COMPLETED	A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).